Hibiscus Health is a next-gen digital metabolic health platform, revolutionizing the early detection, prevention, and management of diabetes, hypertension, and obesity. Our advanced, AI-driven facial scanning technology, accessible through a simple phone camera, marks a significant leap from traditional comprehensive blood screens. This cutting-edge approach not only facilitates early health risk detection but also enables the creation of personalized, data-driven care plans, optimizing both health outcomes and cost savings.Notably, our platform is complemented by a dedicated team of registered dietitians and clinicians, contributing to an impressive 95%+ improvement in clinical outcomes among our users. With a focus on user-friendly experience and measurable progress, we offer a holistic solution that significantly benefits self-funded employer groups and payors. Our approach not only identifies at-risk members proactively but also translates into substantial savings in healthcare costs, showcasing our commitment to both health and economic efficiency.

Precise Behavioral acquired Rose Health in October 2022.Advise on Product, Strategy, and Innovation for Precise Behavioral.Member of the Board of Directors of Precise Behavioral.

Rose leverages deep tech and deep science for the early detection of depression and mood disorders.Recognized by Forbes, Business Insider, DC Inno, Washington Business Journal, Fox News, Fierce Healthcare, Healthcare IT, and others.Rose Health is one of the fastest-growing mental health platforms in the US.Rose Health was acquired by Precise Behavioral in October 2022.

Key Accomplishments:- Evaluated and diligenced M&A process for CareConnect and a top 5 health insurer. - Constructed JV for Northwell and a PE company to create a population health MSO. - Assessed CareConnect and a mobile-based telemedicine provider partnership.

Key Accomplishments:- Directed sourcing and assessment of 50+ investment opportunities, in which, 5 opportunities proceeded to term sheet stage with a significant involvement in the investment process.- Accomplished M&A and growth strategy of portfolio companies.

Key Accomplishments:- Sell-side M&A process for Invacare’s medical device company.- Sell-side M&A process for EasyStand to Rockwood PE.- Served as joint lead arranger in an $850MM recapitalization transaction for Ikaria – a biotherapeutics company.

Key Accomplishments:- Advised a JV developing a new drug delivery technology for its injectable “depot” drug- Performed commercialization, monetization, and related valuation to assist the operational and legal restructuring of Schering-Plough's merger with Merck

Private Equity

Healthcare Investment Analyst and Equity Team Leader of a $1 Million student-led investment fund.

JP Morgan's Healthcare group